Ocular Therapeutix (OCUL) Accumulated Depreciation (2013 - 2025)
Ocular Therapeutix (OCUL) posted quarterly Accumulated Depreciation of $27.5 million for Q4 2025, up 16.45% year-over-year from $23.6 million in Q4 2024, and up 16.45% on a QoQ basis from $23.6 million in Q4 2024.
Ocular Therapeutix (OCUL) Accumulated Depreciation (2013 - 2025) Analysis & Trends
Ocular Therapeutix has reported Accumulated Depreciation for 13 years, with the latest figure at $27.5 million in Q4 2025.
- Accumulated Depreciation for Q4 2025 came in at $27.5 million, up 16.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.5 million (up 16.45% YoY), and the FY2025 annual result was $27.5 million, up 16.45% from the prior year.
- Accumulated Depreciation rose to $27.5 million in Q4 2025, from $23.6 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $27.5 million in Q4 2025 and troughed at $15.2 million in Q4 2021.
- A 5-year average of $20.8 million and a median of $20.3 million in 2023 frame the typical range for Accumulated Depreciation.
- The widest annual swing landed in 2021, when Accumulated Depreciation gained 18.93%; it then rose 13.62% in 2022.
- A 5-year view of Accumulated Depreciation shows it stood at $15.2 million in 2021, then advanced by 13.62% to $17.3 million in 2022, then increased by 17.26% to $20.3 million in 2023, then increased by 16.64% to $23.6 million in 2024, then increased by 16.45% to $27.5 million in 2025.
- Per Business Quant data, the three most recent Accumulated Depreciation figures were $27.5 million in Q4 2025, $23.6 million in Q4 2024, and $20.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27.52 Mn |
| Dec 31, 2024 | 23.63 Mn |
| Dec 31, 2023 | 20.26 Mn |
| Dec 31, 2022 | 17.28 Mn |
| Dec 31, 2021 | 15.21 Mn |
| Dec 31, 2020 | 12.79 Mn |
| Dec 31, 2019 | 10.02 Mn |
| Dec 31, 2018 | 7.63 Mn |
| Dec 31, 2017 | 5.34 Mn |
| Sep 30, 2017 | 4.84 Mn |
| Dec 31, 2016 | 3.82 Mn |
| Dec 31, 2015 | 2.94 Mn |
| Dec 31, 2014 | 2.22 Mn |
| Dec 31, 2013 | 1.68 Mn |